First-in-Human Phase 1 Safety, Pharmacokinetic, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs G1T 38 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors G1 Therapeutics
- 01 May 2017 Status changed from active, no longer recruiting to completed.
- 06 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
- 07 Dec 2016 Planned number of patients changed from 69 to 75.